NeuroPointDx

NeuroPointDX is a small biotechnology company based in Madison, Wisconsin, with a team of four employees. The company focuses on developing innovative diagnostic tools for neurological disorders. NeuroPointDX specializes in metabolomics, a field that analyzes small molecules in biological samples. Through its division Stemina Biomarker Discovery, NeuroPointDX has identified distinct metabolic differences in children with autism spectrum disorder (ASD) and other neurological conditions. These discoveries aim to facilitate earlier diagnosis and more targeted treatment approaches for these children. NeuroPointDX's core differentiator lies in its proprietary metabolomics platform, which allows for the identification of subtle metabolic variations indicative of neurological disorders. The company is actively validating these biomarkers and advancing its diagnostic test through a clinical study called the Children's Autism Metabolome Project (CAMP). Interested parties can visit NeuroPointDX's website at neuropointdx.com for further information.